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Effective gastroretentive drug delivery systems (GRDDS) depend upon the factors
such as the gastric emptying process, gastrointestinal transit time of the dosage form,
drug release from the dosage form and the site of drug absorption. Rapid GI transit leads
to incomplete drug release from the dosage form in the absorption zone. This led to the
development of GRDDS. Several approaches cited in the literature (1–4) include muco-
adhesion, swelling or expansion, modified shape systems, floatation, gastric emptying
delaying devices (5) or simultaneous administration of gastric emptying delaying drugs.
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Tizanidine hydrochloride is an orally administered pro-
kinetic agent that facilitates or restores motility through-
out the length of the gastrointestinal tract. The objective
of the present investigation was to develop effervescent
floating matrix tablets of tizanidine hydrochloride for pro-
longation of gastric residence time in order to overcome
its low bioavailability (34–40 %) and short biological half
life (4.2 h). Tablets were prepared by the direct compres-
sion method, using different viscosity grades of hydroxy-
propyl methylcellulose (HPMC K4M, K15M and K100M).
Tablets were evaluated for various physical parameters
and floating properties. Further, tablets were studied for
in vitro drug release characteristics in 12 hours. Drug re-
lease from effervescent floating matrix tablets was sus-
tained over 12 h with buoyant properties. DSC study re-
vealed that there is no drug excipient interaction. Based
on the release kinetics, all formulations best fitted the Hi-
guchi, first-order model and non-Fickian as the mecha-
nism of drug release. Optimized formulation (F9) was se-
lected based on the similarity factor (f2) (74.2), dissolu-
tion efficiency at 2, 6 and 8 h, and t50 (5.4 h) and was used
in radiographic studies by incorporating BaSO4. In vivo
X-ray studies in human volunteers showed that the mean
gastric residence time was 6.2 ± 0.2 h.
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Among the various approaches, the floating drug delivery systems offer the most
effective, simple and practical approach to achieve increased gastric residence time and
sustained drug release compared to the other methods (4). Based on the mechanism of
buoyancy, non-effervescent and effervescent technologies have been utilized in the de-
velopment of floating drug delivery systems (FDDS). Non-effervescent systems common-
ly use gel-forming or highly swellable cellulose type hydrocolloids. Effervescent systems
utilize swellable polymers and inclusion of gas generating agents, i.e., sodium bicarbon-
ate and citric or tartaric acid (6).
Tizanidine hydrochloride is an orally administered prokinetic agent that facilitates
or restores motility throughout the length of the gastrointestinal tract. Tizanidine is least
absorbed from the lower part of the gastrointestinal tract and better absorbed from the
stomach. The main limitations of the therapeutic effectiveness of tizanidine hydrochlo-
ride is its low bioavailability (30–40 %), short biological half life (4.2 h) and the fact that
it undergoes first pass metabolism. Thus, tizanidine hydrochloride is a candidate for the
development of GRDDS. In the present study, the details of formulation development
and evaluation of effervescent floating tablets of tizanidine hydrochloride are described.
EXPERIMENTAL
Materials
Tizanidine hydrochloride was a gift sample from Symed Lab Ltd., India. Hydroxy-
propyl methylcelluloses (HPMC K4M, K15M, and K100M) were gift samples from Dan-
med Pharmaceuticals, India. Microcrystalline cellulose was obtained from Aurabindo
Laboratories, India. Sodium bicarbonate and magnesium stearate were purchased from
S.D. Fine-Chem. Ltd., India. All other chemicals used were of analytical grade.
Methods
Development of tablets. – Tizanidine hydrochloride tablets were prepared using dif-
ferent viscosity K-grade HPMC polymers such as K4M (4000 cps), K15M (15,000 cps) and
K100M (1,00,000 cps). Preliminary formulations (F1-F4) were studied to optimize the ef-
fervescent concentration. Then, floating tablets were prepared with an optimized con-
centration of effervescent composition. All formulation ingredients were sifted through
a 420-ìm aperture size sieve to get uniform size particles. The mixture was placed in a
polyethylene bag and further mixed for 5 to 10 minutes to ensure a homogeneous mass.
Then, the powder was lubricated with magnesium stearate and talc and compressed on
a 16-station rotary tablet punching machine (Cadmach, India) using 8-mm standard flat-
-face punches. Formulated tablets were round and flat with an average diameter of 8.1 ±
0.2 mm and a thickness of 3.36 ± 0.2 mm. Quantitative composition of tizanidine hydro-
chloride floating matrix tablets is shown is Table I.
Physical characterization of compressed tablets
Compressed tablets were characterized for mass and thickness variation. Mass vari-
ation (20 tablets) was carried out using a digital balance (Shimadzu, Japan) and thick-
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ness (10 tablets) was measured with a digital screw gauge micrometer (Digimatic mi-
crometer Series 293, Mitutoyo, Japan). Crushing strength (6 tablets) was measured with
a Monsanto tester (Campbell Electronics, India), and friability (10 tablets) was determi-
ned (Roche type friabilator, Germany).
The drug content in each formulation was determined by triturating 10 tablets and
powder equivalent to the average mass of one tablet was added in 100 mL of 0.1 mol L–1
HCl, followed by sonicating for 2 h. The drug content was estimated by recording ab-
sorbance at 319 nm using a UV-Visible spectrophotometer (Elico-161, India).
In vitro buoyancy studies
The in vitro buoyancy was determined by floating lag time, as per the method de-
scribed by Rosa et al. (7). The tablet was placed in a 100-mL beaker containing 0.1 mol L–1
HCl. The time required for the tablet to rise to the surface for floating was defined as the
floating lag time and total duration of time the tablet remained buoyant was defined as
total floating time (TFT).
In vitro drug release studies
The release of tizanidine hydrochloride from floating matrix tablets (3 tablets) was
studied using a USP 28 (8) type II (paddle) dissolution apparatus (Electro Lab, India).
The dissolution test was performed using 900 mL 0.1 mol L–1 HCl maintained at 37 ± 0.5 °C
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F1 10 – 70 – 18 76 2 4 180
F2 10 – 70 – 27 67 2 4 180
F3 10 – 70 – 36 58 2 4 180
F4 10 – 70 – 45 49 2 4 180
F5 10 40 – – 36 88 2 4 180
F6 10 60 – – 36 68 2 4 180
F7 10 80 – – 36 48 2 4 180
F8 10 – 30 – 36 98 2 4 180
F9 10 – 40 – 36 88 2 4 180
F10 10 – 60 – 36 68 2 4 180
F11 10 – 80 – 36 48 2 4 180
F12 10 – – 40 36 88 2 4 180
F13 10 – – 60 36 68 2 4 180
F14 10 – – 80 36 48 2 4 180
HPMC – hydroxypropyl methylcellulose, MCC – microcrystalline cellulose
and a rotation speed of 50 rpm. Aliquots of 5 mL were collected at predetermined time
intervals, filtered through a 0.45-mm membrane filter and replenished with an equiva-
lent volume of fresh dissolution medium. Drug content in the samples was determined
at 319 nm after suitable dilutions.
In vivo X-ray studies
The in vivo X-ray studies were approved by the Institutional Human Ethical Com-
mittee of KLR Pharmacy College (New Paloncha, A. P., India). The study was performed
on 3 healthy male human volunteers, weighing between 55 and 70 kg and in an age
group of 25 ± 2 years. Before participation in these studies, a written consent was ob-
tained from the volunteers and an expert radiologist and a physician supervised these
studies. F9 was modified by adding 20 mg of X-ray grade barium sulfate (10 mg of drug
and 10 mg of microcrystalline cellulose were replaced). After overnight fasting, the vol-
unteers were fed low calorie food and the tablet was given to every subject with 200 mL
water. After one hour of tablet ingestion, a glass of water was given to the subject. Gastric
radiography was done after 1, 2, 4 and 6 h. The mean gastric residence time was calculated.
Drug release kinetics
The rate and mechanism of drug release was analyzed by fitting the dissolution da-
ta into several mathematical models, zero-order, first-order, Higuchi and Peppas (9–12).
Dissolution profiles were compared with the similarity factor using the theoretical
release profile as a reference (13). Similarity factor (f2) (14) is a logarithmic, reciprocal
square root transformation to the sum of squared errors. If f2 value is between 50 and
100, the two dissolution profiles are considered to be similar. From the dissolution pro-
files of each formulation, the dissolution efficiency (DE) (15) at 2, 6 and 8 h and t50 was
determined.
Differential scanning calorimetry (DSC)
The physicochemical compatibilities of the drug and excipients used were tested by
performing DSC analyses of pure drug and optimized formulation (F9). DSC curves of
the samples were obtained with a differential scanning calorimeter (DSC 6, Perkin El-
mer, USA). 2–4 mg of sample was placed in an aluminum pan and then crimped with an
aluminum cover. Heating and cooling rates were 10 and 250 °C min–1, respectively. All
measurements were performed over 50–350 °C under a nitrogen purge at 50 mLmin–1.
RESULTS AND DISCUSSION
Physical characterization of tablets
Physical characteristics of the formulated matrix are shown in Table II. To avoid pro-
cessing variables, all batches were produced under similar conditions. The mean hard-
ness of the tablets was 3.2 ± 0.6 kg cm–2, average mass variation was 182 ± 4 mg, mean
thickness was 3.2 ± 0.4 mm and friability ranged from 0.5 to 0.7 % (m/m) (0.6 ± 0.2 %).
The content uniformity of the tablets was 98.9 ± 2.3 %.
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In vitro buoyancy
For determination of optimum in vitro buoyancy and floating lag time, formulations
(F1-F4) were prepared with different concentrations of sodium bicarbonate (10, 15, 20,
and 25 %). Whitehead et al. (16) had demonstrated good correlation between in vitro and
in vivo buoyancy of floating dosage forms. Their results showed that increasing concen-
tration of sodium bicarbonate decreased the floating lag time. At 20 % sodium bicarbon-
ate concentration tablets remained rigid and buoyant for 12 h with a lag time of 125 to
140 seconds, whereas the tablets with 25 % NaHCO3 showed shorter lag time and the
tablet integrity was lost during the study after 6 to 8 h (results not shown). In this study,
penetration of water into tablets with low viscosity HPMC K4M was slow, causing de-
layed gel formation and subsequent increase in the floating lag time and decreased total
floating duration (< 8 h) compared to the tablets prepared with K15M and K100M. F9
showed the best floating lag time of 120 ± 5 s. With the exception of formulations F5 to
F7, all the formulated tablets were buoyant for more than 12 h.
Drug excipient interactions
Fig. 2 represents the DSC curves of pure drug and optimized formulation (F9). A
sharp endothermic peak was observed at 290.1 °C, indicating the melting point of tiza-
nidine hydrochloride. In the DSC thermogram of optimized formulation, the peak was
observed at 284.7 °C. This finding clearly indicates there was no interaction between the
drug and excipients used in the formulation.
In vitro dissolution studies
By using pharmacokinetic parameters of tizanidine hydrochloride, the theoretical drug
release for a 12-h dosage form was calculated. An effective drug plasma concentration
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F5 0.972 0.928 0.945 0.58
F6 0.978 0.954 0.988 0.64
F7 0.968 0.928 0.942 0.68
F8 0.958 0.885 0.948 0.62
F9 0.988 0.919 0.922 0.74
F10 0.977 0.932 0.962 0.56
F11 0.969 0.948 0.906 0.63
F12 0.948 0.926 0.923 0.67
F13 0.969 0.894 0.926 0.64
F14 0.962 0.868 0.936 0.59
R2 – coefficient of determination, n – release exponent of Korsmeyer-Peppas
was maintained when the sustained release formulation released the required quantity
of drug with predetermined kinetics. To achieve this, floating tablets should be formu-
lated so that they release the drug in a predetermined and reproducible manner. The re-
lease of tizanidine hydrochloride from effervescent floating tablets was analyzed by
plotting the cumulative percent drug release against time. The in vitro drug release stud-
ies revealed that formulations F5, F6 and F7 (Fig. 1a) containing 22, 33 and 44 % HPMC
K4M, respectively, were able to sustain the drug release for 4, 6 and 8 h, respectively.
Floating lag time was 435 seconds; total buoyancy was 6 to 8 h and tablet integrity was
poor for HPMC K4M formulations. Drug release profiles of formulations F8 to F11 con-
taining 16.6, 22, 33 and 44 % HPMC K15 M, respectively, are shown in Fig. 1b. For F8,
98 % of the drug was released after 10 hours. 95, 86 and 81 % of drug was released from
formulations F9, F10 and F11, respectively, after 12 h. Formulation F8 underwent swell-
ing and erosion, resulting in faster drug release. In F9, 22 % of HPMC K15M was suffi-
cient to sustain the drug release for 12 h. On increasing the quantity of HPMC K15M up
to 44 %, the release of the drug was too slow and only 81 % of the drug was released. It
was observed that when the polymer concentration was increased, the drug release rate
decreased. Formulation F9 matched the theoretical release profile and floating lag time
of 120 s; for these reasons, F9 was considered the best among all the formulations.
Drug release profiles of formulations F12-F14, composed of HPMC K100M, are
shown in Fig. 1c. The percentage of drug released from these formulations was 91, 83
and 76 %, respectively, after 12 h. This variation was considered to be due to different
polymer concentrations. Release of the drug was faster with lower viscosity grades of
HPMC (K4M) due to lower gel strength, less entanglement and smaller diffusion path
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F14 Fig. 1. Dissolution profiles of tizanidine
hydrochloride floating tablets prepared
with: a) HPMC K4M, b) HPMC K15M, c)
HPMC K100M (mean ± SD, n = 6).
length compared to higher viscosity grades of HPMCs. In all the formulations, polymer
concentration greatly affected the release of the drug. The drug release rate was inver-
sely proportional to the polymer concentration present in the matrix.
Drug release kinetics
The results of kinetic models for tizanidine hydrochloride release from floating ma-
trix tablets are shown in Table II. The coefficient of determination (R2) was used as indi-
cator of the best fitting for each of the models considered. The results revealed that all
formulations of floating matrix tablets fitted best the Higuchi (9) and first-order models
(10). To explore the mechanism of drug release, the results of in vitro data were fitted
into the Korsmeyer and Peppas equation (Mt / M = ktn, where Mt/M is the fraction of
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Fig. 2. DSC curves of: a) tizanidine hydrochloride, b) optimized formulation (F9).
drug released at infinite time, k is the kinetic constant and n is the diffusional exponent
indicative of the mechanism of drug release) (11, 12) characterizing the transport mecha-
nism. The value of n was 0.54–0.78, indicating release governed by the non-Fickian dif-
fusion mechanism.
The optimized formulation was selected based on the similarity factor (f2) (14) va-
lue, dissolution efficiency (15) at 2, 6 and 8 h, and t50 value (Table III). The similarity fac-
tor (f2) of F9, when compared with the theoretical release profile, was found to be 74.2,
which was higher than for other formulations. The other independent model parameters
such as dissolution efficiency and t50 revealed that the drug release profile from formu-
lation F9 was similar to the theoretical release profile.
In vivo X-ray studies
After ingestion of the floating tablets developed by using barium sulfate, the dura-
tion of the tablet in the stomach and upper part of the intestine was monitored by radio-
grams (Fig. 3). The change in the location of the tablet at different time points suggested
that the tablet did not adhere to the gastric mucosa; the mean gastric residence time was
6.2 ± 0.2 h.
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2 h 6 h 8 h
Theoretical 450 ± 5 4.8 38.3 63.1 75.5
F5 435 ± 7 2.4 45.4 b – 50.9
F6 430 ± 5 2.8 35.4 98.4 c 54.6
F7 126 ± 6 3.2 30.1 83.5 97.23 55.6
F8 120 ± 1 3.1 34.2 84.6 97.1 58.2
F9 130 ± 2 5.4 30.3 60.8 73.2 74.2
F10 136 ± 4 6.2 17.8 48.7 62.2 64.2
F11 128 ± 6 7.1 12.2 44.8 57.7 59.8
F12 139 ± 7 7.6 11.9 38.5 55.9 66.4
F13 140 ± 8 8.3 10.2 36.9 48.3 56.7
F14 139 ± 4 8.6 9.12 21.3 44.2 55.2
a Mean ± SD, n = 3.
b 97.7 % drug released in 4 h.
c 98.1 % drug released in 6 h.
CONCLUSIONS
The present study was conducted to develop an effervescent floating drug delivery
system using three grades of HPMC polymer, in different concentrations. Optimized for-
mulation F9 showed an excellent buoyant ability and a suitable drug release pattern. This
could be advantageous in terms of increased bioavailability of tizanidine hydrochloride.
The developed gastroretentive drug delivery system provides advantages of ease of pre-
paration and sustained drug release for 12 h.
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S A @ E T A K
Priprava i vrednovanje {ume}ih plutaju}ih tableta tizanidin hidroklorida
KOMURAVELLY SOMESHWAR, KALYANI CHITHALURU, TADIKONDA RAMARAO i K. K. KALYAN KUMAR
Tizanidin hidroklorid je prokineti~ki agens za peroralnu primjenu koji olak{ava ili
obnavlja mobilnost kroz gastrointestinalni trakt. Cilj rada bio je razvoj {ume}ih pluta-
ju}ih matriksnih tableta tizanidin hidroklorida za produljeno zadr`avanje u `elucu u svr-
hu pobolj{anja niske bioraspolo`ivosti (34–40 %) i produljenja vremena polu`ivota (4,2
h). Tablete su pripravljene metodom izravne kompresije, koriste}i hidroksipropil metil-
celulozu razli~ite viskoznosti (HPMC K4M, K15M i K100M). Odre|eni su razli~iti fizi-
kalni parametri. Osloba|anje ljekovite tvari in vitro bilo je polagano tijekom 12 sati, a
tablete su imale svojstvo plutanja. Prema DSC ispitivanja nema interakcije s pomo}nim
tvarima. Kineti~ka ispitivanja pokazuju da osloba|anje iz svih pripravaka slijedi Higu-
chijev model, kinetiku prvog reda i ne-Fickov zakon. Na temelju faktora sli~nosti (f2)
(74,2), osloba|anja ljekovite tvari nakon 2, 6 i 8 h, te vremena polu`ivota t50 (5,4 h) iza-
brana je optimirana formulacija (F9) i upotrebljena u radiografi~kim ispitivanjima koja
uklju~uju BaSO4. In vivo ispitivanja rendgenskim zrakama na dobrovoljcima pokazala su
da je srednje vrijeme zadr`avanja u `elucu bilo 6,2 ± 0,2 h.
Klju~ne rije~i: tizanidin hidroklorid, sustav za isporuku lijekova sa zadr`avanjem u `elucu, pluta-
ju}e tablete, kinetika osloba|anja
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